Carmat (ALCAR) - Total Assets
Based on the latest financial reports, Carmat (ALCAR) holds total assets worth €42.43 Million EUR (≈ $49.61 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Carmat (ALCAR) shareholders funds for net asset value and shareholders' equity analysis.
Carmat - Total Assets Trend (2009–2024)
This chart illustrates how Carmat's total assets have evolved over time, based on quarterly financial data.
Carmat - Asset Composition Analysis
Current Asset Composition (December 2024)
Carmat's total assets of €42.43 Million consist of 76.3% current assets and 23.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 11.1% |
| Accounts Receivable | €4.25 Million | 10.0% |
| Inventory | €19.81 Million | 46.7% |
| Property, Plant & Equipment | €9.37 Million | 22.1% |
| Intangible Assets | €73.00K | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Carmat's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Carmat (ALCAR) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Carmat's current assets represent 76.3% of total assets in 2024, an increase from 46.4% in 2009.
- Cash Position: Cash and equivalents constituted 11.1% of total assets in 2024, up from 4.2% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 46.7% of total assets.
Carmat Competitors by Total Assets
Key competitors of Carmat based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.12 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.00 Billion |
|
Lumos Diagnostics Holdings Ltd
AU:LDX
|
Australia | AU$20.81 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Ok Biotech Co Ltd
TW:4155
|
Taiwan | NT$3.89 Billion |
|
Promimic AB
ST:PRO
|
Sweden | Skr75.71 Million |
|
Memphasys Ltd
AU:MEM
|
Australia | AU$10.45 Million |
Carmat - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 2.07 | 6.85 |
| Quick Ratio | 0.66 | 0.90 | 6.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €13.28 Million | €21.95 Million | €50.34 Million |
Carmat - Advanced Valuation Insights
This section examines the relationship between Carmat's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1174.22 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -20.0% |
| Total Assets | €42.43 Million |
| Market Capitalization | $6.37 Million USD |
Valuation Analysis
Below Book Valuation: The market values Carmat's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Carmat's assets decreased by 20.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Carmat (2009–2024)
The table below shows the annual total assets of Carmat from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €42.43 Million ≈ $49.61 Million |
-20.05% |
| 2023-12-31 | €53.07 Million ≈ $62.04 Million |
-37.62% |
| 2022-12-31 | €85.07 Million ≈ $99.46 Million |
+23.46% |
| 2021-12-31 | €68.91 Million ≈ $80.56 Million |
+15.16% |
| 2020-12-31 | €59.84 Million ≈ $69.95 Million |
-7.30% |
| 2019-12-31 | €64.55 Million ≈ $75.46 Million |
+75.26% |
| 2018-12-31 | €36.83 Million ≈ $43.06 Million |
-47.27% |
| 2017-12-31 | €69.85 Million ≈ $81.66 Million |
+86.32% |
| 2016-12-31 | €37.49 Million ≈ $43.83 Million |
+333.42% |
| 2015-12-31 | €8.65 Million ≈ $10.11 Million |
-38.40% |
| 2014-12-31 | €14.04 Million ≈ $16.42 Million |
-36.13% |
| 2013-12-31 | €21.98 Million ≈ $25.70 Million |
+11.61% |
| 2012-12-31 | €19.70 Million ≈ $23.03 Million |
-47.37% |
| 2011-12-31 | €37.43 Million ≈ $43.76 Million |
+77.82% |
| 2010-12-31 | €21.05 Million ≈ $24.61 Million |
+247.80% |
| 2009-12-31 | €6.05 Million ≈ $7.08 Million |
-- |
About Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.